Management of Barrett’s Esophagus

Stephen R. Broderick

doi:10.1016/B978-0-323-79683-5.00502-4

Management of Barrett’s Esophagus

Stephen R. Broderick

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Barrett’s esophagus (BE) is the major risk factor associated with development of esophageal adenocarcinoma. BE is the result of long-standing gastroesophageal reflux disease (GERD); thus, initial management is aimed at identification and treatment of underlying GERD. Once BE is identified and GERD addressed, surveillance for progression to dysplasia is mandatory. Endoscopic therapies are employed to address BE with dysplasia or intramucosal adenocarcinoma. In some patients with high risk features, esophagectomy is indicated.

Original language	English (US)
Title of host publication	Current Surgical Therapy
Publisher	Elsevier
Pages	19-23
Number of pages	5
ISBN (Electronic)	9780323796835
ISBN (Print)	9780323796842
DOIs	https://doi.org/10.1016/B978-0-323-79683-5.00502-4
State	Published - Jan 1 2023

Keywords

adenocarcinoma
Barrett’s
dysplasia
endoscopy
esophagectomy
esophagus

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-79683-5.00502-4

Cite this

@inbook{55a8fcb24abd4691be3ce9e1001a0a9e,

title = "Management of Barrett{\textquoteright}s Esophagus",

abstract = "Barrett{\textquoteright}s esophagus (BE) is the major risk factor associated with development of esophageal adenocarcinoma. BE is the result of long-standing gastroesophageal reflux disease (GERD); thus, initial management is aimed at identification and treatment of underlying GERD. Once BE is identified and GERD addressed, surveillance for progression to dysplasia is mandatory. Endoscopic therapies are employed to address BE with dysplasia or intramucosal adenocarcinoma. In some patients with high risk features, esophagectomy is indicated.",

keywords = "adenocarcinoma, Barrett{\textquoteright}s, dysplasia, endoscopy, esophagectomy, esophagus",

author = "Broderick, \{Stephen R.\}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-79683-5.00502-4",

language = "English (US)",

isbn = "9780323796842",

pages = "19--23",

booktitle = "Current Surgical Therapy",

publisher = "Elsevier",

}

TY - CHAP

T1 - Management of Barrett’s Esophagus

AU - Broderick, Stephen R.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Barrett’s esophagus (BE) is the major risk factor associated with development of esophageal adenocarcinoma. BE is the result of long-standing gastroesophageal reflux disease (GERD); thus, initial management is aimed at identification and treatment of underlying GERD. Once BE is identified and GERD addressed, surveillance for progression to dysplasia is mandatory. Endoscopic therapies are employed to address BE with dysplasia or intramucosal adenocarcinoma. In some patients with high risk features, esophagectomy is indicated.

AB - Barrett’s esophagus (BE) is the major risk factor associated with development of esophageal adenocarcinoma. BE is the result of long-standing gastroesophageal reflux disease (GERD); thus, initial management is aimed at identification and treatment of underlying GERD. Once BE is identified and GERD addressed, surveillance for progression to dysplasia is mandatory. Endoscopic therapies are employed to address BE with dysplasia or intramucosal adenocarcinoma. In some patients with high risk features, esophagectomy is indicated.

KW - adenocarcinoma

KW - Barrett’s

KW - dysplasia

KW - endoscopy

KW - esophagectomy

KW - esophagus

UR - https://www.scopus.com/pages/publications/105011465831

UR - https://www.scopus.com/pages/publications/105011465831#tab=citedBy

U2 - 10.1016/B978-0-323-79683-5.00502-4

DO - 10.1016/B978-0-323-79683-5.00502-4

M3 - Chapter

AN - SCOPUS:105011465831

SN - 9780323796842

SP - 19

EP - 23

BT - Current Surgical Therapy

PB - Elsevier

ER -

Management of Barrett’s Esophagus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this